A prospective observational study evaluating c-MET expression and EGFR gene mutation correlation with erlotinib response in second line treatment for advanced/metastatic non-small cell lung cancer patients

被引：0
作者：
Park, Cheol-Kyu
Choi, Yoo-Duk
Oh, In-Jae
Lee, Jung-Eun
Lee, Shin Yup
Jang, Tae-Won
Ryu, Jeong-Seon
Kim, Young-Chul
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2773
引用
收藏
页数：2
相关论文
共 50 条
  • [41] c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.
    Heist, Rebecca Suk
    Motwani, Monica
    Barlesi, Fabrice
    Goldman, Jonathan Wade
    Kelly, Karen
    Sun, Yan
    Wu, Jun
    Bach, Bruce Allen
    Camidge, D. Ross
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] ERLOTINIB AS SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ECONOMIC MODELING (EM) RESULTS
    Santos, E. A., V
    Buschinelli, C. T.
    Ferracini, M.
    Pepe, C.
    Estanislao, M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [43] Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
    Kaburagi, Takayuki
    Satoh, Hiroaki
    Hayashihara, Kenji
    Endo, Takeshi
    Hizawa, Nobuyuki
    Kurishima, Koichi
    Nishimura, Yoshihiro
    Hashimoto, Toshio
    Nakamura, Hiroyuki
    Kishi, Koji
    Inagaki, Masaharu
    Nawa, Takeshi
    Ichimura, Hideo
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Fukuoka, Toshihiko
    Shinohara, Yoko
    Kamiyama, Koichi
    Sato, Yukio
    Sakai, Mitsuaki
    Matsumura, Takeshi
    Uchiumi, Keiko
    Furukawa, Kinya
    [J]. ONCOLOGY LETTERS, 2013, 5 (02) : 435 - 439
  • [44] Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC)
    Jimenez, U.
    Gurpide, A.
    Isla, D.
    Garcia-Campelo, R.
    Firvida, J.
    Vinolas, N.
    Jaen, A.
    Montalar, J.
    Regueiro, P.
    Massuti, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Effectiveness of erlotinib in Critical Care Unit in patients with non-small cell lung cancer with EGFR mutation
    Dewolf, M.
    Dayen, C.
    Garoute, C.
    Khamis, W.
    Fourrier, M.
    Rousselle, F.
    Sadki, M.
    Le Meunier, F.
    Suguenot, R.
    Lecuyer, E.
    Bentayeb, H.
    Douadi, Y.
    Berna, P.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2017, 73 (03) : 135 - 139
  • [46] OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/IV NON-SMALL CELL LUNG CANCER
    Mehic, Bakir
    Stanetic, Mirko
    Tinjic, Liuljeta
    Smoljanvic, Vlatka
    [J]. BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2008, 8 (04) : 386 - 390
  • [47] Expression profiles of EGFR, c-Met, and mTOR/Wnt alternative signaling pathway proteins in non-small cell lung cancer
    Shearrow, Caleb
    Crees, Zachary
    Girard, Jennifer
    Harrington, Kymberly
    Arasi, Kavin
    Bertram, Ceyda
    Nowak, Andrew
    Lin, Leo
    Sheu, Bonnie
    Palani, Sunil
    Puri, Neelu
    [J]. CANCER RESEARCH, 2015, 75
  • [48] MUTATION ANALYSIS OF THE EGFR GENE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN XINJIANG
    Shi, Yi
    Pang, Xue-Lian
    Ma, Zhi-Ping
    Cui, Wen-Li
    Zhang, Wei
    Ma, Yu-Qing
    [J]. ACTA MEDICA MEDITERRANEA, 2021, 37 (06): : 3363 - 3368
  • [49] Mutation pattern of EGFR gene in Peruvian patients with non-small cell lung cancer
    Ruiz, Rossana
    Galvez-Nino, Marco
    Santos, Marco
    Doimi, Franco
    Mas, Luis
    Belmar-Lopez, Carolina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Multimarker immunohistochemistry of non-small cell lung carcinomas: Correlation with EGFR mutation and response to treatment
    Beheshti, J.
    Mark, E.
    Sabo, E.
    Janne, P.
    Sequist, L.
    Joshi, V.
    Jackman, D.
    Iafrate, A. J.
    Wang, L.
    Meyerson, M.
    Lindeman, N.
    [J]. LABORATORY INVESTIGATION, 2007, 87 : 318A - 318A
12345